CN102336746A - 一类新型的二元酸茄尼醇烷基替加氟二酯制备及其抗癌作用 - Google Patents
一类新型的二元酸茄尼醇烷基替加氟二酯制备及其抗癌作用 Download PDFInfo
- Publication number
- CN102336746A CN102336746A CN2011101919359A CN201110191935A CN102336746A CN 102336746 A CN102336746 A CN 102336746A CN 2011101919359 A CN2011101919359 A CN 2011101919359A CN 201110191935 A CN201110191935 A CN 201110191935A CN 102336746 A CN102336746 A CN 102336746A
- Authority
- CN
- China
- Prior art keywords
- tegafur
- buddhist nun
- nun alcohol
- eggplant buddhist
- eggplant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960001674 tegafur Drugs 0.000 title claims abstract description 126
- -1 solanesol alkyl tegafur diesters Chemical class 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- AFPLNGZPBSKHHQ-UHFFFAOYSA-N Betulaprenol 9 Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCO AFPLNGZPBSKHHQ-UHFFFAOYSA-N 0.000 title claims abstract 5
- 230000001093 anti-cancer Effects 0.000 title description 3
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 claims abstract description 28
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical group C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
- AFPLNGZPBSKHHQ-MEGGAXOGSA-N solanesol Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CO AFPLNGZPBSKHHQ-MEGGAXOGSA-N 0.000 claims abstract 2
- 244000061458 Solanum melongena Species 0.000 claims description 132
- 235000002597 Solanum melongena Nutrition 0.000 claims description 132
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 64
- 238000006243 chemical reaction Methods 0.000 claims description 58
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 50
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 47
- 238000010898 silica gel chromatography Methods 0.000 claims description 40
- 238000003756 stirring Methods 0.000 claims description 40
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 30
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 28
- 150000007520 diprotic acids Chemical class 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 16
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 15
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 15
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 15
- 239000011259 mixed solution Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 9
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 150000008064 anhydrides Chemical class 0.000 claims description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 229920002554 vinyl polymer Chemical group 0.000 claims description 3
- 150000008065 acid anhydrides Chemical class 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 238000003760 magnetic stirring Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 abstract description 10
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 72
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 72
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 48
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 48
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 34
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 25
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 25
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 238000012544 monitoring process Methods 0.000 description 24
- 239000003208 petroleum Substances 0.000 description 24
- QSAWQNUELGIYBC-UHFFFAOYSA-N cyclohexane-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCCCC1C(O)=O QSAWQNUELGIYBC-UHFFFAOYSA-N 0.000 description 18
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 125000004494 ethyl ester group Chemical group 0.000 description 16
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 230000008021 deposition Effects 0.000 description 12
- 230000008030 elimination Effects 0.000 description 12
- 238000003379 elimination reaction Methods 0.000 description 12
- 238000003810 ethyl acetate extraction Methods 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 12
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 6
- 230000012010 growth Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- JUGRTVJQTFZHOM-UHFFFAOYSA-N 1,1,1-tribromo-2-methylpropan-2-ol Chemical compound CC(C)(O)C(Br)(Br)Br JUGRTVJQTFZHOM-UHFFFAOYSA-N 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- MUTGBJKUEZFXGO-OLQVQODUSA-N (3as,7ar)-3a,4,5,6,7,7a-hexahydro-2-benzofuran-1,3-dione Chemical compound C1CCC[C@@H]2C(=O)OC(=O)[C@@H]21 MUTGBJKUEZFXGO-OLQVQODUSA-N 0.000 description 3
- KMOUUZVZFBCRAM-OLQVQODUSA-N (3as,7ar)-3a,4,7,7a-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1C=CC[C@@H]2C(=O)OC(=O)[C@@H]21 KMOUUZVZFBCRAM-OLQVQODUSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 3
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- QKLXBIHSGMPUQS-FGZHOGPDSA-M (3r,5r)-7-[4-(4-fluorophenyl)-2,5-dimethyl-1-phenylpyrrol-3-yl]-3,5-dihydroxyheptanoate Chemical compound CC1=C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C(C)N1C1=CC=CC=C1 QKLXBIHSGMPUQS-FGZHOGPDSA-M 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- WGCIUTGSVKJKAI-UHFFFAOYSA-N CCCN(C(C(F)=CN1C2OCCC2)=O)C1=O Chemical compound CCCN(C(C(F)=CN1C2OCCC2)=O)C1=O WGCIUTGSVKJKAI-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 101100391174 Dictyostelium discoideum forC gene Proteins 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 150000003944 halohydrins Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110191935.9A CN102336746B (zh) | 2011-07-11 | 2011-07-11 | 一类二元酸茄尼醇烷基替加氟二酯制备及其抗癌作用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110191935.9A CN102336746B (zh) | 2011-07-11 | 2011-07-11 | 一类二元酸茄尼醇烷基替加氟二酯制备及其抗癌作用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102336746A true CN102336746A (zh) | 2012-02-01 |
CN102336746B CN102336746B (zh) | 2014-04-30 |
Family
ID=45512742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110191935.9A Expired - Fee Related CN102336746B (zh) | 2011-07-11 | 2011-07-11 | 一类二元酸茄尼醇烷基替加氟二酯制备及其抗癌作用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102336746B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107090082A (zh) * | 2017-04-10 | 2017-08-25 | 河南大学 | 一种具有肿瘤组织还原敏感性的茄尼醇衍生物、其制备方法和应用 |
CN115784842A (zh) * | 2022-10-26 | 2023-03-14 | 贵州汇腾科技有限公司 | 废次烟草中高值成分茄尼醇的制备方法及应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4340760A (en) * | 1980-04-23 | 1982-07-20 | Nisshin Flour Milling Co., Ltd. | Monophenylamine derivatives |
CN1762936A (zh) * | 2005-09-23 | 2006-04-26 | 云南科恩生物工程有限公司 | 一种茄呢基溴的制备工艺及其精制方法 |
-
2011
- 2011-07-11 CN CN201110191935.9A patent/CN102336746B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4340760A (en) * | 1980-04-23 | 1982-07-20 | Nisshin Flour Milling Co., Ltd. | Monophenylamine derivatives |
CN1762936A (zh) * | 2005-09-23 | 2006-04-26 | 云南科恩生物工程有限公司 | 一种茄呢基溴的制备工艺及其精制方法 |
Non-Patent Citations (2)
Title |
---|
孟丽丽: "新型青蒿素衍生物的合成及其抗肿瘤活性的初步研究", 《湖南大学硕士学位论文》 * |
田智勇,等: "含酰亚胺结构的替加氟衍生物的合成及其抗肿瘤活性", 《河南大学学报(自然科学版)》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107090082A (zh) * | 2017-04-10 | 2017-08-25 | 河南大学 | 一种具有肿瘤组织还原敏感性的茄尼醇衍生物、其制备方法和应用 |
CN107090082B (zh) * | 2017-04-10 | 2018-11-20 | 河南大学 | 一种具有肿瘤组织还原敏感性的茄尼醇衍生物、其制备方法和应用 |
CN115784842A (zh) * | 2022-10-26 | 2023-03-14 | 贵州汇腾科技有限公司 | 废次烟草中高值成分茄尼醇的制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102336746B (zh) | 2014-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Quirante et al. | Ferrocene–indole hybrids for cancer and malaria therapy | |
CN108864024B (zh) | 一类灯盏乙素苷元氮芥类衍生物及其制备方法和用途 | |
CN112110969B (zh) | 3-硝基-1-甲酸乙酯-7-氮杂吲哚的三氮唑糖苷衍生物及其制备方法和应用 | |
CN107629089A (zh) | 高活性的他克林‑铂(ii)配合物及其合成方法和应用 | |
CN114105978A (zh) | 一种氧化吲哚类化合物及其制备方法和应用 | |
CN114014872A (zh) | 青蒿琥酯衍生物及其制备方法和应用 | |
CN111499676A (zh) | 4-氯-3-硝基-1-对甲苯磺酰基-7-氮杂吲哚衍生物及其制备方法和应用 | |
CN108484632B (zh) | 青蒿素-苯胺基喹唑啉类衍生物及其制备方法和应用 | |
CN102336746B (zh) | 一类二元酸茄尼醇烷基替加氟二酯制备及其抗癌作用 | |
CN112972478B (zh) | 灰黄霉素施密特重排衍生物在制备抗肿瘤药物中的应用 | |
CN110642740B (zh) | 异斯特维醇酰胺衍生物及其制备方法 | |
CN108864089B (zh) | 一种吲哚并吡啶酮药物分子及其制备方法和应用 | |
CN101613354B (zh) | 一种制备吡喃并香豆素衍生物的方法 | |
CN106008540A (zh) | 有抗肿瘤活性的芳香杂环酸酯类鬼臼毒素衍生物及制备方法与应用 | |
CN110156735A (zh) | 芒柄花黄素衍生物及其制备方法和应用 | |
CN113683594B (zh) | 一种喹啉-苯并咪唑盐类化合物及其合成方法和应用 | |
CN105541713A (zh) | 一种异喹啉化合物及其合成方法 | |
CN112225745B (zh) | 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途 | |
CN111362962B (zh) | 去甲斑蝥素羧酸四氟苄酯及其合成方法 | |
CN111533706B (zh) | 一种1,4,6-三取代1,2-二氢-三嗪类化合物的制备方法 | |
CN111116477B (zh) | 多拉米胺的合成工艺 | |
CN111253415B (zh) | 去甲斑蝥素羧酸三氟苄酯及其合成方法和应用 | |
CN108976217B (zh) | 一种多西他赛-1,2,3,-三氮唑化合物及其合成工艺和应用 | |
CN104098524B (zh) | 1-间甲氧基苯甲酰基-3-苯基-1,4-二氢-1,2,4,5-四嗪及制备和应用 | |
CN105949139A (zh) | 一种仲丁基二苯基四嗪甲酰胺化合物及制备和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SICHUAN UNIVERSITY Free format text: FORMER OWNER: GUOKANG MEDICINE INDUSTRY CO LTD, SICHUAN Effective date: 20130218 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Yin Shufan Inventor after: Xiao Keyi Inventor after: Dai Ya Inventor after: Li Ying Inventor before: Xiao Keyi Inventor before: Shi Wanqi Inventor before: Yin Shufan Inventor before: Dai Ya Inventor before: Li Ying |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: XIAO KEYI SHI WANQI YIN SHUFAN DAI YA LI YING TO: YIN SHUFAN XIAO KEYI DAI YA LI YING Free format text: CORRECT: ADDRESS; FROM: 610041 CHENGDU, SICHUAN PROVINCE TO: 610021 CHENGDU, SICHUAN PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130218 Address after: 610021, No. 24, south section of Ring Road, Sichuan, Chengdu Applicant after: Sichuan University Address before: 610041, No. 13, building 11, Huada mall, No. 266 Wuhou Temple street, Chengdu, Sichuan Applicant before: Sichuan Guokang Pharmaceutical Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140430 Termination date: 20180711 |